Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4

Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4

Abstract In this multicenter, open-label, single-arm, Phase II study with Simon two-stage optimum design (NCT04361370), we investigate the efficacy and safety of triplet maintenance (olaparib, pembrolizumab, bevacizumab) in patients with platinum-sensitive recurrent ovarian cancer who are wild-type...

Full description

Bibliographic Details
Main Authors: Yoo-Na Kim, Boram Park, Jae Weon Kim, Byoung Gie Kim, Sang Wun Kim, Hee Seung Kim, Chel Hun Choi, Myong Cheol Lim, Natalie YL Ngoi, David SP Tan, Jung-Yun Lee
Format: Article
Language:English
Published: Nature Portfolio 2023-09-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-40829-2

Internet

https://doi.org/10.1038/s41467-023-40829-2

Similar Items